Pulse Biosciences (NASDAQ:PLSE) Insider Sells 20,000 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00. Following the transaction, the insider owned 43,298 shares of the company’s stock, valued at approximately $1,018,801.94. The trade was a 31.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kevin Patrick Danahy also recently made the following trade(s):

• On Tuesday, February 17th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $23.63, for a total value of $472,600.00.
• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $21.45, for a total value of $429,000.00.
• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $25.20, for a total value of $504,000.00.

Pulse Biosciences Stock Performance

Shares of PLSE stock traded up $0.66 during mid-day trading on Tuesday, reaching $23.67. 303,171 shares of the company were exchanged, compared to its average volume of 434,878. The company has a market capitalization of $1.60 billion, a P/E ratio of -20.95 and a beta of 1.77. The business’s 50 day simple moving average is $15.75 and its 200 day simple moving average is $15.90. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $26.30.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its position in shares of Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock valued at $291,000 after purchasing an additional 3,991 shares during the period. Russell Investments Group Ltd. grew its holdings in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares during the period. ExodusPoint Capital Management LP raised its position in Pulse Biosciences by 14.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 25,122 shares of the company’s stock worth $345,000 after acquiring an additional 3,258 shares in the last quarter. Barclays PLC lifted its holdings in Pulse Biosciences by 8.5% in the 4th quarter. Barclays PLC now owns 27,652 shares of the company’s stock valued at $380,000 after acquiring an additional 2,164 shares during the last quarter. Finally, State Street Corp lifted its holdings in Pulse Biosciences by 6.0% in the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after acquiring an additional 25,187 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Mizuho set a $30.00 target price on Pulse Biosciences in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pulse Biosciences has a consensus rating of “Hold” and a consensus price target of $26.00.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.